Speaker Biography
Christopher C. Gallen, MD, PhD
President & CEO
Neuromed Pharmaceuticals
Dr. Gallen joined Neuromed in July 2004 as President & CEO and has led the company to two rounds of its five rounds of private equity financing, a transformative licensing deal and research collaboration with Merck & Co. and an acquisition of the U.S. marketing rights to a Phase 3 chronic pain product from ALZA Corporation.
Dr. Gallen has an extensive track record in clinical and corporate development and has been instrumental in commercializing several drugs. Prior to Neuromed, Dr. Gallen was Vice President and Chief of Operations, Clinical Research and Development at Wyeth Research, in charge of global clinical operations including clinical trial management, data management, biostatistics, clinical communications, procedural compliance and training and was a key driver in the re-engineering of Wyeth Clinical Research and Development. Prior to Wyeth, Dr. Gallen was VP of Clinical Research at Pharmacia and was responsible for overseeing global CNS development and clinical operations for all specialties and clinical research in the Western Hemisphere. He was also a key leader in the successful re-engineering of Pharmacia leading to a position of Site Head for the Kalamazoo R&D Site overseeing all aspects of R&D for CNS and Infectious Diseases.
Previous positions include President of the CRO division at Premier Research Worldwide, where he was a key contributor to a successful IPO, and Senior Director of Medical and Scientific Services at Quintiles International Clinical Research Corporation where he drove the pivotal development programs for several successful neurotherapeutics. Dr. Gallen received his M.D. and Ph.D. (Biochemistry) from the Emory University School of Medicine in Atlanta, Georgia and completed residencies in Psychiatry at Stanford and in Neurology at UCSD.